Arno Hazekamp published the first peer-reviewed study on gamma-irradiated cannabis in 2016. Ten years later, that paper is still the document a German importer's quality team reaches for when they ask a Canadian supplier one question: was this batch treated, and what did the treatment cost the terpene profile?
Cannabis irradiation is a post-harvest decontamination step that uses gamma rays, X-rays or electron beams to cut microbial counts in dried flower so a batch can meet pharmacopoeial acceptance criteria. For an exporter it carries two separate weights. It is a compliance tool in Canada, and it is a commercial signal in Germany, Australia and Israel, read straight off the analytical file that travels with the lot.
Most Licensed Producers treat this as a lab problem. It is a specification problem. It starts in the drying room and ends on a pharmacy shelf.
What cannabis irradiation does to export flower, and what it doesn't
Irradiation damages microbial DNA. Three sources are used commercially on cannabis: gamma rays from a cobalt-60 source, X-rays from an electrically generated tube, and electron beams. All three are ionising. Radio frequency treatment gets grouped with them in conversation, but it is not ionising at all. It agitates moisture inside the bud and kills through heat.
The evidence on what treatment costs you is narrower than the argument around it. Hazekamp's 2016 study in Frontiers in Pharmacology compared four cannabis varieties before and after a standard gamma protocol. THC and CBD content did not change. Water content did not change. The microscopic structure of the trichomes did not change. The measurable effect was a reduction in some terpenes, concentrated in the volatile monoterpenes, with the profile staying qualitatively the same.
A later analysis of gamma-treated cannabis biomass reported delivered doses between 15 and 20.8 kGy, with post-treatment aerobic and yeast and mould counts falling below 10 CFU per gram. That is the whole trade in one line. Near-total microbial reduction, paid for in aroma.
Where the trade-off actually sits
Monoterpenes such as myrcene and linalool are the compounds that move. Sesquiterpenes hold up better. A procurement manager buying against a cannabinoid specification will see nothing unusual on the certificate of analysis. A pharmacy buyer who opens the jar will notice within seconds.
The useful question is not whether irradiation harms flower. It is which buyer you are quoting. One is paying for potency, the other is paying for smell, and they will not accept the same batch.
The microbial limits your buyer is actually testing against
Under the Cannabis Regulations, section 91 requires microbial and chemical contaminant testing on each lot or batch, and section 92 requires validated methods. Section 93(3) is the provision exporters should read twice. Tolerance limits must be drawn from a publication listed in Schedule B to the Food and Drugs Act, and they must suit the intended and reasonably foreseeable use of the product. Health Canada confirmed to licence holders that European Pharmacopoeia chapter 5.1.8 limits stay acceptable for dried cannabis, with compliance expected by 31 March 2021.
Ph. Eur. 5.1.8 covers herbal medicinal products for oral use and sorts them into categories carrying different acceptance criteria. Chapter 5.1.4 sets criteria by route of administration instead, and the inhalation profile is much tighter: a TAMC of 102 CFU per gram and a TYMC of 101 CFU per gram, with specified organisms absent. Which chapter and which category apply is a decision someone has to make and defend. It is not a default.
Australia states its numbers plainly. The Therapeutic Goods Administration applies TGO 100 clause 11(1) to medicinal cannabis: a maximum TAMC of 200 CFU per gram, a maximum TYMC of 20 CFU per gram, and absence of Staphylococcus aureus and Pseudomonas aeruginosa in 1 gram. The TGA has itself acknowledged that botanical dosage forms can struggle against those figures.
| Market | Reference standard | Headline microbial criterion | Confirm before you ship |
|---|---|---|---|
| Canada | Schedule B pharmacopoeia, Cannabis Regulations s.93(3) | Ph. Eur. 5.1.8 accepted for dried cannabis | Limits chosen for inhaled use, not oral |
| Germany and EU | Ph. Eur. 5.1.8 and 5.1.4 | Category set by monograph and product spec | Which category the importer has written |
| Australia | TGO 100, clause 11(1) | TAMC 200 CFU/g, TYMC 20 CFU/g | Whether an alternative provision was approved |
| Israel | IMC-GAP and IMC-GMP framework | Set by the importer's written specification | Get the spec before sampling begins |
Here is where Licensed Producers get caught, and it is rarely the science. Pharmacopoeial figures are acceptance criteria that a manufacturer or distributor converts into a binding product specification, and a supply agreement can be written tighter than the pharmacopoeia it cites. Our breakdown of export testing requirements across four markets sets out how far those specifications diverge in practice. You are not being tested against Ph. Eur. You are being tested against whatever your buyer wrote down.
Germany's irradiation rules and the declaration your file must carry
German law generally prohibits placing irradiated medicinal products on the market. The exception runs through the AMRadV, the ordinance governing irradiation of medicinal products, which sets the conditions a treated product has to satisfy. Because Canadian and Dutch flower arriving in Germany is routinely treated, that exemption is the working norm for cannabis rather than a rare carve-out. Miss the conditions and distribution of the product can stop.
Import and wholesale also sit behind a licence from BfArM under section 4(1) of the Medizinal-Cannabisgesetz. That licence belongs to your importer, not to you, but the documentation trail it produces is shared. Treatment status travels with the batch on the analytical paperwork, which means it reaches the pharmacy preparing the magistral formulation. Our guide to Canadian export requirements for Germany covers the rest of that documentation chain.
Timing turned this from a technical footnote into a commercial one. On 30 July 2026, Germany removed dried cannabis flower from statutory health insurance reimbursement under section 31(6) SGB V, with no transitional protection for patients already in stable treatment. The Bundesverband pharmazeutischer Cannabinoidunternehmen put the number of affected patients at roughly 65,000. Flower became a private-pay product for most of them almost overnight. Private-pay patients choose, and after price, what they choose on is aroma.
So, plainly: if you cannot state a batch's treatment status in writing before the sample ships, you are not ready to quote a German importer. That answer is a prerequisite to the tender, not an item to be resolved during it.
The 4-step remediation decision path
Remediation is a fallback, not a plan. The cheapest microbial reduction available to any Licensed Producer is the load that never grew in the first place.
Step 1. Prevent, then remediate
Environmental control, harvest handling and post-harvest moisture management do more for yeast and mould counts than any machine downstream of them. Water activity is the lever most producers underuse. Our guide to water activity as an export quality standard covers the working range, and drying and curing standards for export flower covers the handling that holds it there. GACP-aligned practice is where importers expect to see all of it recorded.
Step 2. Fix the specification before harvest
Decide which pharmacopoeial chapter and category govern the batch, and obtain the buyer's written specification, before that batch exists. A lot that fails a specification nobody read is a lot you remediate under time pressure, at whatever dose the treatment facility runs as its default.
Step 3. Match the method to the specification
The methods are not interchangeable, and penetration is the property that separates them:
- Gamma, cobalt-60 source: penetrates dense buds, needs a licensed radioactive-source facility, and is the best-documented route for cannabis
- X-ray: electrically generated with no radioactive source and good penetration, though chamber size caps throughput
- Electron beam: electrically generated and fast, but shallower penetration can leave interior contamination in dense flower
- Radio frequency: non-ionising and volumetric, and needs tight control to protect terpenes and moisture content
- Surface treatments such as ozone and UV-C: act on the exterior only, and are unreliable inside a dense bud
Step 4. Validate it, then write it down
Dose mapping, validated test methods under section 92, an ISO/IEC 17025 accredited laboratory, and batch records that let an importer's quality person trace a treatment back to a specific lot. Disclosure belongs in the same file as the data. An importer who discovers a treatment after release does not log it as a technical finding. They log it as a reason to re-qualify the supplier.
AlphaLeaf is a Health Canada Licensed Producer in Montreal growing indoor, hand-trimmed flower from refined genetics. Our lots carry ISO-certified batch testing data and full traceability records, and we hold export authorisation under the Cannabis Act, which is the evidence German and Australian importers ask for before any conversation about remediation begins.
If you want to work through the documentation behind a specific cultivar, start with our certifications and quality records, then reach the export team through the contact page. Bring your specification. We will tell you what we can meet untreated. That is the entire conversation.
Frequently Asked Questions
Is irradiated cannabis allowed in Germany?
Yes, but through an exception. German law generally prohibits placing irradiated medicinal products on the market, and treated cannabis is supplied under the conditions set by the AMRadV, the ordinance governing irradiation of medicinal products. Canadian and Dutch flower reaching German pharmacies is routinely treated, so exporters should confirm with their importer that the exemption conditions are documented for the batch.
Does irradiation reduce THC potency?
No. Hazekamp's 2016 study in Frontiers in Pharmacology compared four cannabis varieties before and after standard gamma treatment and found no change in THC or CBD content, no change in water content, and no change in the microscopic structure of the trichomes. The measurable effect was limited to a reduction in some terpenes, mainly the volatile monoterpenes.
What microbial limits does Health Canada apply to dried cannabis?
Section 93(3) of the Cannabis Regulations requires tolerance limits drawn from a publication listed in Schedule B to the Food and Drugs Act and appropriate to the intended and reasonably foreseeable use of the product. Health Canada has confirmed that European Pharmacopoeia chapter 5.1.8 limits remain acceptable for dried cannabis. The harder part is the second half of the test: the limits you select must suit inhaled use rather than oral use.
What are Australia's microbial limits for medicinal cannabis?
The Therapeutic Goods Administration applies TGO 100 clause 11(1) to medicinal cannabis products. That sets a maximum total aerobic microbial count of 200 CFU per gram, a maximum total yeast and mould count of 20 CFU per gram, and absence of Staphylococcus aureus and Pseudomonas aeruginosa in 1 gram. The TGA has acknowledged that botanical dosage forms can find those criteria difficult to meet.
Which decontamination method preserves terpenes best?
There is no single answer, because penetration and terpene retention pull against each other. Gamma and X-ray penetrate dense buds reliably and are the best-documented routes for cannabis. Electron beam is faster but shallower. Radio frequency is non-ionising and can be gentler on aroma when tightly controlled. Surface methods such as ozone and UV-C do not reliably reach contamination inside a bud.
Do international buyers have to be told a batch was irradiated?
Treat it as mandatory regardless of jurisdiction. Treatment status travels with the batch on the analytical documentation and reaches the pharmacy or distributor downstream, so it will surface. Stating it in writing before samples ship is standard practice with German and Australian importers, and discovering it after release is usually treated as grounds to re-qualify the supplier.
